Virus filtration is the last safety barrier before the final drug product. Its robustness is by definition conditioned by everything upstream — including the hydrodynamic stability of the TFF system that feeds it. This page examines the documented relationship between flux instability, progressive fouling, and the risk of compromised viral clearance, and the role that a stable TFF process plays in preserving validated operating conditions throughout the batch duration. AFRM® does not replace virus filter validation. It preserves the conditions under which that validation was conducted — for the entire batch.

01 —

Flux and Pressure as Viral Safety Variables

The regulatory and scientific literature is consistent on a key point: worst-case conditions for viral retention are not primarily defined by viral load in the feedstream, but by the operating conditions of the filter itself. Johnson et al. (2022) [1] explicitly identify low transmembrane pressure, pressure transitions, low flux, and flow pauses as the primary risk factors for viral breakthrough — not high viral concentration.

Peles et al. (2024) [2] quantify this relationship for the Viresolve® Pro membrane: viral LRV scales with the virus Péclet number of the permeate flux. Reducing flux from 108 to 5.4 L/m²/h reduces single-layer retention by more than 2 logs. Process disruptions cause an immediate transient increase in virus transmission. The critical distinction — established in both Johnson et al. and Kozaili et al. (2024) [3] — is between controlled low flux under optimized conditions and uncontrolled low flux caused by fouling or process instability. Only the former is compatible with robust and reproducible viral clearance.

LRV vs. Permeate Flux — Viresolve® Pro (single layer) · Peles et al. 2024
5 20 40 80 108 Permeate Flux (L/m²/h) 1 2 3 4 5 LRV (single layer) 4-log Risk zone (low flux / fouling)

Schematic representation of Peles et al. (2024) asymptotic LRV data for single-layer Viresolve® Pro. Commercial devices employ two layers; expected LRV is approximately double the values shown. The risk zone illustrates the flux regime reached when TFF fouling reduces permeate flow over time.

02 —

The Connection to the Upstream TFF System

In a continuous perfusion process, the virus filter does not operate in isolation. It receives a feedstream whose hydrodynamic profile is directly conditioned by the state of the TFF membrane upstream. Progressive fouling in the TFF circuit manifests as: a declining permeate flux over time, shifting the Péclet number toward the low-retention regime documented by Peles et al.; increasing and fluctuating transmembrane pressure; and growing variability in feedstream composition — including aggregate concentration — which Kozaili et al. (2024) [3] identify as the primary cause of runs terminated early due to unacceptable pressure buildup on the virus filter.

This means that a TFF system that fails to maintain hydrodynamic stability over the course of a batch introduces into the virus filter feedstream exactly the conditions that the literature classifies as worst-case for viral retention.

TFF Stability → Feedstream Quality → Viral Clearance
TFF — Fouling
dR/dt > 0
flux declining
▶
low Pe
instability
Virus Filter
low flux
pressure spikes
▶
LRV risk
LRV
variable
worst-case
— WITH AFRM® —
TFF — Stable
dR/dt ≈ 0
flux quasi-stationary
▶
stable Pe
clean feed
Virus Filter
constant flux
validated range
▶
LRV robust
LRV
predictable
reproducible

Without TFF stability, flux decay and pressure instability push virus filter operation into the worst-case regime. With dR/dt≈0, the feedstream delivered to the virus filter remains within the hydrodynamic envelope for which the clearance has been validated.

03 —

What Process Stability Guarantees

A TFF process with dR/dt≈0 — maintained hydraulic resistance throughout the batch — delivers a stable feedstream to the downstream virus filter: constant flux, stable pressure, consistent feedstream composition. This does not replace virus filter validation, but it preserves the operating conditions within which that validation was performed.

The constancy of the sieving coefficient during the batch — a direct consequence of maintaining membrane cleanliness — also ensures that molecular selectivity does not drift as fouling would otherwise narrow effective pore diameter. This property is particularly relevant for applications where product quality attributes (CQAs) are sensitive to separation consistency across the batch duration, including the concentration of aggregates delivered to the virus filter. The physical foundations of this operating principle are examined in detail in the technical white paper.

04 —

Continuous Bioprocessing: The Amplified Challenge

In continuous bioprocessing the challenge is structurally more complex. The virus filter operates for days rather than hours, at lower fluxes to extend operational lifetime, and receives a feedstream whose composition evolves continuously. Kozaili et al. (2024) [3] document that product stability and feedstream quality are the determining factors for success or failure of continuous viral clearance — and that aggregate buildup, which accumulates slowly over time, is the primary mechanism leading to unacceptable pressure increases and early run termination. An inline prefilter can mitigate this effect, but does not eliminate the root cause.

Johnson et al. (2022) [1] note that scale-down models for continuous virus filtration validation must faithfully represent the flow and pressure conditions of the actual process — including the variations that fouling introduces over time. A system that prevents irreversible cake compaction maintains the process within the design space for which the scale-down model was constructed, reducing the risk of divergence between validation conditions and manufacturing reality.

In continuous bioprocessing, the virus filter does not see a constant feedstream. It sees the cumulative consequence of everything that has happened in the TFF circuit over the preceding hours. Process stability is not a secondary concern — it is a precondition for predictable viral clearance.

05 —

Implications for Qualification

The qualification perimeter of AFRM® as an add-on system — device classification, IQ/OQ pathway, comparability protocol, and onboarding package — is described in detail in the Technology section.

What the peer-reviewed literature cited here establishes independently is that hydrodynamic stability of the TFF circuit has documented implications for downstream viral clearance predictability. This is not an AFRM® claim — it is a physical relationship quantified by independent academic and industrial research groups including Penn State, MilliporeSigma, Asahi Kasei, and Merck & Co.

The scientific rationale for why TFF stability is a relevant condition for virologial safety — not only for operational efficiency — is therefore grounded in an established and citable body of evidence, independent of the AFRM® architecture itself.

For a strategic reading of why process stability by design differs from incremental improvement of existing TFF methods, see Reading AFRM® through Innovation Theory.

Physical foundations and control architecture
The deterministic principles underlying process stability in TFF — kinetic invariance, dimensionless scaling, and bounded uncertainty — are examined in full in the technical white paper.

Read the White Paper →

References

  1. Johnson, S. A., Chen, S., Bolton, G., Chen, Q., Lute, S., Fisher, J., & Brorson, K. (2022). Virus filtration: A review of current and future practices in bioprocessing. Biotechnology and Bioengineering, 119, 743–761. FDA Office of Biotechnology Products, Amgen, Genentech, Parexel.
  2. Peles, J., Cacace, B., Carbrello, C., Giglia, S., Hersey, J., & Zydney, A. L. (2024). Virus retention during constant-flux virus filtration using the Viresolve® Pro membrane including process disruption effects. Journal of Membrane Science, 709, 123059. Penn State University & MilliporeSigma. Received May 2024 · Accepted July 2024.
  3. Kozaili, J., Rayfield, W., Gospodarek, A., Brower, M., & Strauss, D. (2024). Adapting virus filtration to continuous processing: Effects of product and process variability on filtration performance. Biotechnology Progress, 40(2), e3407. Asahi Kasei Bioprocess America & Merck & Co. Accepted October 2023.